Darzalex faspro 1,800MG-30,000 15ML
Ended Awarded Last action
- Contract number
- SPE2DR26F0A5C
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $32,629
Award facts
- Contract value 100% obligated
- $32,628.85 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $32,628.85 and issued on January 27, 2026, represents a competitively awarded, firm fixed-price purchase of DARZALEX FASPRO 1,800MG-30,000 15ML pharmaceutical product. The Defense Logistics Agency awarded the contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, with performance at the same location. The contract carries an ultimate completion date of February 18, 2026 and includes no set-aside designation, indicating the award was made through open competition. This delivery order is executed under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999.00 vehicle through December 2031 that serves as the primary procurement mechanism for comprehensive pharmaceutical and medical supply support to military healthcare systems globally.
DARZALEX FASPRO is a subcutaneous formulation of daratumumab, a monoclonal antibody used in oncology to treat multiple myeloma and other blood cancers. The DLA's Medical Supply Chain regularly procures specialty pharmaceuticals through its prime vendor contracts to support military treatment facilities and veteran healthcare programs. AmerisourceBergen's extensive portfolio of federal pharmaceutical contracts demonstrates its established capability to deliver a diverse range of specialty medications, generic drugs, vaccines, and medical supplies across multiple therapeutic domains to federal healthcare systems. The firm fixed-price structure and competitive award reflect standard federal pharmaceutical procurement practices for essential medical commodities supporting the Department of Defense healthcare mission.
Quick answers
Who was awarded contract SPE2DR26F0A5C?
SPE2DR26F0A5C was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26F0A5C worth?
The government has obligated $32,629 on SPE2DR26F0A5C.
Is contract SPE2DR26F0A5C an order under another contract?
Yes. SPE2DR26F0A5C is a delivery order under SPE2DR25D3103, an indefinite delivery contract.
Was contract SPE2DR26F0A5C competed?
The extent of competition for SPE2DR26F0A5C was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award